BeOne Medicines Opens Shanghai Innovation Center – A 55,855 m² Self‑Built R&D Hub Purpose‑Built for AI‑Driven Antibody Discovery and Next‑Generation ADCs

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced the official opening of its Shanghai Innovation Center, a wholly self‑built research and development campus that will serve as one of the global biotech's key hubs for early‑stage drug discovery.…

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.